Redwood Shores, Calif.-based Procept said the 30-patient Francais Water study is designed to evaluate the safety and effectiveness of prostate ablation via waterjet in treating benign prostate hyperplasia in men aged 45 to 80. The primary outcome is total change in International Prostate Symptom score at 6 months, with a final data collection slated for August 2018, according to ClinicalTrials.gov.
Get the full story at our sister site, The Robot Report.
The post Procept BioRobotics launches AquaBeam trial in France appeared first on MassDevice.
from MassDevice http://ift.tt/2ijW9gn
Cap comentari:
Publica un comentari a l'entrada